• A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway 

      Grytten, Nina; Aarseth, Jan Harald; Lunde, Hanne Marie; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2015-01-14)
      Objective: Investigate the incidence of multiple sclerosis during 1953–2013 and estimate the prevalence rate of MS on 1 January 2003 and 2013 in Hordaland County, Western Norway. Methods: All patients with onset of disease ...
    • Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction 

      Løken-Amsrud, Kristin Ingeleiv; Myhr, Kjell-Morten; Bakke, Søren Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Bjørnarå, Bård T.; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve (Peer reviewed; Journal article, 2013-01-22)
      Objective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship ...
    • The Association Between Exposure to Interferon-Beta During Pregnancy and Birth Measurements in Offspring of Women With Multiple Sclerosis 

      Burkill, Sarah; Vattulainen, Pia; Geissbuehler, Yvonne; Sabido Espin, Meritxell; Popescu, Catrinel; Suzart-Woischnik, Kiliana; Hillert, Jan; Artama, Miia; Verkkoniemi-Ahola, Auli; Myhr, Kjell-Morten; Cnattingius, Sven; Korhonen, Pasi; Montgomery, Scott; Bahmanyar, Shahram (Peer reviewed; Journal article, 2019-12-30)
      Background: Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of ...
    • The cost of multiple sclerosis in Norway 

      Svendsen, Bjørn; Myhr, Kjell-Morten; Nyland, Harald Inge; Aarseth, Jan Harald (Peer reviewed; Journal article, 2010-11-16)
      Health economic aspects have been increasingly important during introduction of new treatments for multiple sclerosis. As a partial response for Norway, a costof- illness study was carried out to estimate the yearly cost ...
    • Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta 

      Gavasso, Sonia; Mosleth, Ellen Færgestad; Marøy, Tove Helene; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. (Peer reviewed; Journal article, 2014-02-19)
      Background: Anti interferon-beta (IFN-β) neutralizing antibodies (NAb) affect efficacy of treatment of multiple sclerosis patients, but exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated. ...
    • Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model 

      Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten; Aksnes, Lage; Mørk, Sverre; Bø, Lars (Peer reviewed; Journal article, 2011-10-20)
      Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of ...
    • Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM 

      Kroksveen, Ann Cathrine; Aasebø, Elise; Vethe, Heidrun; van Pesch, Vincent; Franciotta, Diego; Teunissen, Charlotte E.; Ulvik, Rune Johan; Vedeler, Christian A.; Myhr, Kjell-Morten; Barsnes, Harald; Berven, Frode (Peer reviewed; Journal article, 2013-01)
      In the present study, we aimed to discover cerebrospinal fluid (CSF) proteins with significant abundance difference between early multiple sclerosis patients and controls, and do an initial verification of these proteins ...
    • Disease-modifying treatments for multiple sclerosis – a review of approved medications 

      Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2015-11-13)
      Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing remitting MS (RRMS). ...
    • The economic impact of multiple sclerosis to the patients and their families in Norway 

      Svendsen, Bjørn; Grytten, Nina; Bø, Lars; Aarseth, Hallvard Gilje; Smedal, Tori; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2018-12)
      Background: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objective: We aimed to estimate the magnitude of these economic costs in ...
    • Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome 

      Aasebø, Elise; Opsahl, Jill Anette; Bjørlykke, Yngvild; Myhr, Kjell-Morten; Kroksveen, Ann Cathrine; Berven, Frode S. (Peer reviewed; Journal article, 2014-03-05)
      Over the last years there has been an increased focus on the importance of knowing the effect of pre-analytical influence on the proteomes under study, particularly in the field of biomarker discovery. We present three ...
    • Employment among patients with multiple sclerosis - A population study 

      Lunde, Hanne Marie; Telstad, Wenche; Torkildsen, Nina Agnethe Grytten; Kyte, Lars; Aarseth, Jan; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2014-07-23)
    • Fingolimod does not enhance cerebellar remyelination in the cuprizone model 

      Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind (Journal article, 2015-08)
      Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected ...
    • Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations 

      Olafsson, S.; Stridh, P.; Bos, Steffan Daniel; Ingason, Andrés; Euesden, J; Sulem, Patrick; Thorleifsson, Gudmar; Gustafsson, O; Geirsson, AJ; Jóhannesson, Ari J.; Thorsson, AV; Ludviksson, BR; Sigurgeirsson, Bardur; Jonasson, JG; Olafsson, E; Kristjansdottir, H; Olafsson, JH; Orvar, KB; Benediktsson, Rafn; Bjarnason, Ragnar; Kristjansdottir, Sjofn; Gislason, Thorarin; Valdimarsson, T; Mikaelsdottir, E; Sigurdsson, S; Jonsson, S; Rafnar, Thorunn; Aarsland, Dag; Djurovic, Srdjan; Fladby, Tormod; Knudsen, Gun Peggy S.; Celius, Elisabeth Gulowsen; Myhr, Kjell-Morten; Gröndal, Gerdur; Steinsson, K; Valdimarsson, Helgi; Bjornsson, Sigurdur; Bjornsdottir, US; Bjornsson, Einar S.; Nilsson, B; Andreassen, Ole Andreas; Alfredsson, Lars; Hillert, Jan; Kockum, Ingrid; Másson, Gísli; Thorsteinssdottir, U; Gudbjartsson, Daniel F.; Stefansson, H; Hjaltason, H; Harbo, Hanne Flinstad; Olsson, T; Jonsdottir, I; Stefansson, K (Peer reviewed; Journal article, 2017)
      A meta-analysis of publicly available summary statistics on multiple sclerosis combined with three Nordic multiple sclerosis cohorts (21,079 cases, 371,198 controls) revealed seven sequence variants associating with multiple ...
    • Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial 

      Storm-Larsen, Christopher; Myhr, Kjell-Morten; Farbu, Elisabeth; Midgard, Rune; Nyquist, Kaja Beate; Broch, Line; Berg-Hansen, Pål; Hov, Johannes Espolin Roksund; Holmøy, Trygve (Peer reviewed; Journal article, 2019)
      Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis, which has been associated ...
    • High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018 

      Willumsen, Johannes Sverre; Aarseth, Jan Harald; Myhr, Kjell-Morten; Midgard, Rune (Journal article; Peer reviewed, 2020)
      Objective To determine prevalence and longitudinal trends in incidence of MS in Møre and Romsdal County, Western Norway, from 1950 to 2018. Methods Retrospective longitudinal population-based observational study. All ...
    • Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort 

      Westerlind, Helga; Imrell, Kerstin; Ramanujam, Ryan; Myhr, Kjell-Morten; Celius, Elisabeth Gulowsen; Harbo, Hanne Flinstad; Oturai, Annette Bang; Hamsten, Anders; Alfredsson, Lars; Olsson, Tomas; Kockum, Ingrid; Koski, Timo; Hillert, Jan (Peer reviewed; Journal article, 2015)
      In an attempt to map chromosomal regions carrying rare gene variants contributing to the risk of multiple sclerosis (MS), we identified segments shared identical-by-descent (IBD) using the software BEAGLE 4.0’s refined IBD ...
    • In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis 

      Kroksveen, Ann Cathrine; Guldbrandsen, Astrid; Vaudel, Marc; Lereim, Ragnhild Reehorst; Barsnes, Harald; Myhr, Kjell-Morten; Torkildsen, Øivind; Berven, Frode (Peer reviewed; Journal article, 2017)
      In the current study, we conducted a quantitative in-depth proteome and deglycoproteome analysis of cerebrospinal fluid (CSF) from relapsing-remitting multiple sclerosis (RRMS) and neurological controls using mass spectrometry ...
    • In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR) 

      Guldbrandsen, Astrid; Vethe, Heidrun; Farag, Yehia Mohamed Mokhtar; Oveland, Eystein; Garberg, Hilde Kristin; Berle, Magnus Foldal; Myhr, Kjell-Morten; Opsahl, Jill Anette; Barsnes, Harald; Berven, Frode (Peer reviewed; Journal article, 2014-11)
      In this study, the human cerebrospinal fluid (CSF) proteome was mapped using three different strategies prior to Orbitrap LC-MS/MS analysis: SDS-PAGE and mixed mode reversed phase-anion exchange for mapping the global CSF ...
    • Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity 

      Holmøy, Trygve; Løken-Amsrud, Kristin Ingeleiv; Bakke, Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Myhr, Kjell-Morten; Michelsen, Annika; Aukrust, Pål; Ueland, Thor (Peer reviewed; Journal article, 2013-09-19)
      Background. Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the ...
    • Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study 

      Bjørnevik, Kjetil Lauvland; Riise, Trond; Cortese, Marianna; Holmøy, Trygve; Kampman, Margitta Theodora; Magalhaes, Sandra; Myhr, Kjell-Morten; Wolfson, Christina; Pugliatti, Maura (Peer reviewed; Journal article, 2015-05-26)
      Background: Several recent studies have found a higher risk of multiple sclerosis (MS) among people with a low level of education. This has been suggested to reflect an effect of smoking and lower vitamin D status in the ...